The startup develops honey-incorporated absorbable membranes for wound care, combining the properties of multiple therapeutic products to enhance healing. This technology specifically targets chronic and acute wounds, improving treatment efficacy for medical practitioners.
Funding
$8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Chronic and acute wounds, including diabetic ulcers and surgical wounds, present a significant burden due to slow healing, risk of infection, and potential complications. Traditional wound care methods may not always provide optimal healing environments, leading to prolonged recovery times and increased healthcare costs.
Solution
SweetBio develops advanced wound care products incorporating Manuka honey and collagen to promote faster and more effective healing. Their flagship products, APIS® and VERIS™, are designed to manage a variety of wounds by creating a moist environment, reducing bacterial load, and stimulating the release of growth factors. APIS® is tailored for chronic wounds like diabetic ulcers, while VERIS™ addresses acute wounds such as those from skin cancer surgery. These products aim to simplify the healing process, reduce closure times, and improve patient outcomes compared to standard care.
Target Audience
The primary target audience includes healthcare professionals such as wound care specialists, surgeons, and nurses treating patients with chronic and acute wounds, as well as patients seeking advanced and accessible wound care solutions.
Features
- Bioengineered collagen matrix infused with Manuka honey and hydroxyapatite
- FDA-cleared for managing chronic and acute wounds, including diabetic ulcers, pressure ulcers, and surgical wounds
- Demonstrated 2x faster wound closure compared to standard of care in clinical evaluations
- In vitro studies show significant reduction in Staphylococcus Aureus and Pseudomonas Aeruginosa bacterial load
- Reduces MMP-9 expression and triggers the release of pro-regenerative growth factors (FGFb and VEGF)
- Absorbent sheet format for mess-free application and easy use
- Covered by CMS (Centers for Medicare & Medicaid Services), ensuring affordability and accessibility for patients